Home » Drug pipeline in development in 2024 for Alzheimer’s. « Medicine in the Library

Drug pipeline in development in 2024 for Alzheimer’s. « Medicine in the Library

by admin
Drug pipeline in development in 2024 for Alzheimer’s.  « Medicine in the Library

Drug pipeline in development in 2024 for Alzheimer’s.

Posted by giorgiobertin on April 25, 2024

Cummings’ highly regarded 2024 Annual Report is featured in Alzheimer’s and Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer’s Association. According to this year’s data, there are 164 active trials and 127 unique treatments, a decrease of about 10% from the previous year which saw a record 187 active trials and 141 unique treatments.

Some of this year’s accomplishments include:

76% are disease-modifying treatments that aim to slow memory decline
34% are biologic therapies administered intravenously or through other injections
12% are cognitive enhancing agents intended to improve memory
13% are medications for behavioral symptoms, such as agitation
31% are repurposed agents approved for other diseases, such as cancer or Parkinson’s disease
One prediction we can confidently make is that we should be prepared for more complex biologic therapies that require intravenous infusion and careful monitoring of side effects; more similar to cancer therapies”Cummings said.

Read the full text of the article:

Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer’s disease drug development pipeline: 2024. A&D Transl Res & Clin Interv. 2024;10(2):e12465. doi: 10.1002/trc2.1246

This entry was posted on aprile 25, 2024 a 2:54 PM and is filed under News-research. Tagged: pharmacology, neurology. You can follow any responses to this entry through the RSS 2.0 feed.

You can leave a responseor trackback from your own site.

See also  "Forward in the war against Hamas despite international pressure" | Raid on Rafah refugee camp, victims

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy